SAB Biotherapeutics, Inc.
SABS
$2.19
$0.13956.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.70K | 377.80K | 1.32M | 1.51M | 2.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.70K | 377.80K | 1.32M | 1.51M | 2.78M |
| Cost of Revenue | 30.14M | 29.96M | 30.45M | 27.10M | 23.29M |
| Gross Profit | -30.02M | -29.58M | -29.13M | -25.58M | -20.51M |
| SG&A Expenses | 11.80M | 12.71M | 13.78M | 26.19M | 25.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.94M | 42.67M | 44.23M | 53.29M | 48.57M |
| Operating Income | -41.82M | -42.29M | -42.91M | -51.78M | -45.79M |
| Income Before Tax | -37.06M | -34.28M | -34.11M | -45.57M | -40.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.06 | -34.28 | -34.11 | -45.57 | -40.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.06M | -34.28M | -34.11M | -45.57M | -40.32M |
| EBIT | -41.82M | -42.29M | -42.91M | -51.78M | -45.79M |
| EBITDA | -38.52M | -38.71M | -38.12M | -46.82M | -40.82M |
| EPS Basic | -3.99 | -3.70 | -3.68 | -5.84 | -5.69 |
| Normalized Basic EPS | -2.50 | -2.31 | -2.30 | -3.65 | -3.56 |
| EPS Diluted | -3.99 | -3.70 | -3.68 | -5.84 | -5.69 |
| Normalized Diluted EPS | -2.50 | -2.31 | -2.30 | -3.65 | -3.56 |
| Average Basic Shares Outstanding | 37.14M | 37.10M | 37.05M | 34.52M | 30.50M |
| Average Diluted Shares Outstanding | 37.14M | 37.10M | 37.05M | 34.52M | 30.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |